The Ministry of Health (MoH) has reassured Kenyans that there is no shortage of Antiretroviral (ARV) drugs in the country, despite widespread concerns. Kenya Medical Supplies Agency (KEMSA) CEO Waqo Erjesa emphasized on Wednesday that current stock levels are sufficient, guaranteeing consistent supply to all clients.
In tandem, Health Director-General Patrick Amoth disclosed that the ministry expects to receive 2.34 million doses of Bacillus Calmette–Guerin (BCG) vaccines, crucial for Tuberculosis (TB) prevention, by the end of January. Amid a nationwide shortage, counties have been instructed to document individuals who miss the vaccine during this critical period.
“We are working toward sustainable solutions to prevent future shortages,” Dr. Amoth assured during a press briefing.
The BCG vaccine shortage has been a pressing issue, with reports indicating a complete stockout in some counties for over a month. This has heightened health risks for infants, who are particularly vulnerable to contracting TB. The Ministry of Health’s data highlights that TB prevalence among children under 15 years rose to 13% in 2024, up from 12% in 2023. Alarmingly, 139,000 people developed TB in Kenya in 2023, 17,000 of whom were children.
The ARV situation, although stable now, was previously concerning, given Kenya’s growing HIV burden. According to recent statistics, the country recorded 16,752 new HIV infections in 2024, with women comprising the majority (10,784 cases) compared to men (5,968 cases). Additionally, AIDS-related deaths totaled 20,480 last year, including 2,607 children, underscoring the ongoing public health challenge.
Efforts to strengthen the supply chain and ensure a stable supply of essential medications and vaccines are ongoing, as the government remains committed to mitigating health threats posed by HIV/AIDS and TB.
The MoH has urged citizens to remain vigilant and ensure infants are vaccinated once the BCG doses arrive, reinforcing the importance of preventive care in safeguarding public health.
